Chronic obstructive pulmonary disease (COPD) affects millions of French people, yet it remains underrecognized. Experts warn that these patients are among the most vulnerable to COVID-19, prompting urgent calls for action from patient advocacy groups.
As outlined by Inserm, COPD is a chronic inflammatory bronchial disease primarily linked to smoking. It causes progressive narrowing and permanent obstruction of the airways, leading to significant respiratory distress. In 2000, it impacted 1.7 million people in France; today, that figure has risen to nearly 4 million. A 2017 study in The Lancet Respiratory Medicine reported 3.2 million global deaths from COPD in 2015.
With the COVID-19 epidemic accelerating in France, attention has turned to this overlooked group. On February 25, 2020, the France BPCO association sent a letter to Health Minister Olivier Véran, advocating for COPD patients as the most vulnerable to COVID-19.
France BPCO highlights the 700,000 French COPD patients in severe condition, urging a shift in focus from broad groups like the elderly, children, diabetics, or those with cardiovascular issues. The association requests a nationwide awareness campaign in healthcare facilities to better identify and support these patients. They also advocate for FFP2 masks to be extended beyond healthcare workers to COPD patients.
COVID-19 typically presents with mild symptoms like cough and fever, but severe cases lead to acute respiratory distress syndrome—a critical failure of lung function. For those with pre-existing COPD, infection poses a potentially fatal threat.
Source
Related Articles:
